Inborn pigment skin malformation in a child: practice of diagnostics

Background. Pediatric skin melanoma is very rare, it differs in a number of features from adult skin melanoma. Early diagnostics of this highly malignant tumor is a key prerequisite for effective treatment. The same methods are commonly used which are applied for diagnostics of adult melanoma in the course of diagnostics of skin melanoma in children. Appropriateness of this approach deserves validation.

The aim of this work is to describe procedures of diagnostics of a pigment skin malformation in a child.

Case report. Girl aged 5 months entered pediatric clinic of the FSBI “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation with inborn tumor in a wrist joint area. Hemangioma had been suggested formerly at residence place. In the course of diagnostics in N.N. Blokhin National Medical Research Center of Oncology the following complex of approaches was used: ultrasound scanning, magnetic resonance imaging, trepanobiopsy, open biopsy. Tissues from the latter were examined histologically on hematoxylin and eosin — stained slides. Immunohistochemical study was also done by means of revelation of determinants of cell proliferation, antigens of melanocytic differentiation, proteins commonly used as strictly melanoma markers as well as antigens of tissue compatibility. The conclusion was done about nodular pigment cell skin melanoma. Excision of the tumor was carried out. Relapse-free period lasts for 12 months at present.

Conclusion. Procedures are described of diagnostics and treatment of a 5-month-old girl with skin melanoma in a wristjoint area. In the course of diagnostics approaches were used which are commonly applied when identifying a more frequent and better explored adult skin melanoma. Prolongation of studies is desirable to validate these approaches for diagnostics of pediatric pigment skin tumors.

1. Sekulic A., Haluska P., Miller A.J. et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008;83(7):825-46. DOI: 10.4065/83.7.825.

2. Bastian B.C. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014;9:239-71. DOI: 10.1146/annurev-pathol-012513-104658.

3. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA J Clin 2018;68(1):7-30. DOI: 10.3322/caac.21442.

4. Malignant malformations in Russia(morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinsky, G.V. Petrov. Moscow: 2017. (In Russ.).

5. Men’ T.Kh., Doroshenko M.B., Aliev M.D. Cutaneous malignant melanoma in children and adolescens: population-based epidemiological study. Sarkomy kostei, myagkikh tkanei i opukholi kozhi = Bone and soft tissue sarcomata; skin tumors 2011;2:55-60 (In Russ.).

6. Men’ T.Kh., Rykov M.Yu., Polyakov V.G. Malignant malformations in children in Russia: main indices and trends. Rossiyskiy onkologicheskiy zhurnal = Russian oncological journal 2015;20(2):43—7 (In Russ.).

7. Livestro D.P., Kaine E.M., Michaelson J.S. et al. Melanoma in the young: differences and similarities with adult melanoma: a case-controlled analysis. Cancer 2007;110(3):614—24. DOI: 10.1002/cncr.22818.

8. Averbook B.J., Lee S.J., Delman K.A. et al. Pediatric melanoma: analysis of an international registry. Cancer 2013;119(22):4012—9. DOI: 10.1002/cncr.28289.

9. Clarkson K.S., Sturdgess I.C., Molyneux A.J. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (antytyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001;54(3):196—200. DOI: 10.1136/jcp.54.3.196.

10. Weinstein D., Leininger J., Hamby C., Safai B. Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol 2014;7(6):13—24.

11. Karagiannis P., Fittall M., Karagiannis S.N. Evaluating biomarkers in melanoma. Front Oncol 2015;4:383. DOI: 10.3389/fonc.2014.00383.

12. Testa U., Castelli G., Pelosi E. Melanoma: genetic abnormalities, tumor progression, clonal evolution and tumor initiating cells. Med Sci (Basel) 2017;5(4): 28. DOI: 10.3390/medsci5040028.

13. Baryshnikov A.Yu., Tonevitsky A.G. Monoclonal antibodies in laboratory and clinic. Chapter 5.1. Monoclonal antibodies aHLA1 (ICO 53) against monomorphic determinants of HLA class I antigens. Moscow, 1997:110—2 (In Russ.).

14. Uguen A., Talagas M., Costa S. et al. A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma. Diagn Pathol 2015;26(10):195. DOI: 10.1186/s13000-015-0431-9.

15. Jonjic N., Dekanic A., Glavan N. et al. Cellular blue nevus diagnosed following excision of melanoma: a challenge in diagnosis. Case Rep Pathol 2016;2016:8107671. DOI: 10.1155/2016/8107671.

16. Karim R.Z., Li W., Sanki A. et al. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors. Int J Surg Pathol 2009;17(5): 361—7. DOI: 10.1177/1066896909336177.

17. Oba J., Nakahara T., Abe T. et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci 2011;62(2):116—123. DOI: 10.1016/j.jdermsci.2011.02.011.

18. Viray H., Bradley W.R., Schalper K.A. et al. Marginal andjoint distribution of S100, HMB-45 and Melan-A across a large series of cutaneous melanomas. Arch Pathol Lab Med 2013;137(8):1063—73. DOI: 10.5858/arpa.2012-0284-OA.

19. Nybakken G.E., Sargen M., Abraham R. et al. MITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferations. Am J Dermatopathol 2013;35(1):25—9. DOI: 10.1097/DAD.0b013e31825666c3.

20. Li M., Zhang B., Sun B. et al. A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis. J Exp Clin Cancer Res 2010;29:109. DOI: 10.1186/1756-9966-29-109.

21. Ruiter D.J., Bhan A.K., Harrist T.J. et al. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 1982;129(6):2808—15.

22. Carretero R., Wang E., Rodriguez A.I. et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012;131(2):387—395. DOI: 10.1002/ijc.26471.

23. Scalvenzi M., Palmisano F., Cacciapuoti S. et al. Giant congenital melanocytic naevus with proliferative nodules mimicking congenital malignant melanoma: a case report and review of the literature of congenital melanoma. Case Rep Dermatol Med 2013;2013: 473635. DOI: 10.1155/2013/473635.

24. Volgareva G.M., Zavalishina L.E., Kazubskaya T.P. et al. Molecular approaches for the diagnostics of pediatric pigment skin malformations: four cases. Onkopediatria = Oncopediatrics 2017;4(4):294—300 (In Russ.).